Clinical trials with leukemia stem cell targeting agents in CML
| Agent . | Target or survival factor pathway . | Clinical trial . |
|---|---|---|
| As2O3 | PML inhibition | NCT01397734 |
| Hydroxychloroquine | Autophagy inhibition | NCT01227135 |
| BMS-833923 | Hedgehog pathway inhibition | NCT01218477 |
| Interferon | Multiple mechanisms | NCT00219739, NCT02001818, NCT01872442 |
| LDE225 | Hedgehog pathway inhibition | NCT01456676 |
| Panobinostat | Histone deacetylase inhibition | NCT00451035 |
| Pioglitazone | PPARγ activation | NCT01751425, NCT02973711 |
| Ruxolitinib | JAK2 inhibition | NCT02889003 |
| Zileuton | ALOX5 inhibition | NCT02047149 |
| Agent . | Target or survival factor pathway . | Clinical trial . |
|---|---|---|
| As2O3 | PML inhibition | NCT01397734 |
| Hydroxychloroquine | Autophagy inhibition | NCT01227135 |
| BMS-833923 | Hedgehog pathway inhibition | NCT01218477 |
| Interferon | Multiple mechanisms | NCT00219739, NCT02001818, NCT01872442 |
| LDE225 | Hedgehog pathway inhibition | NCT01456676 |
| Panobinostat | Histone deacetylase inhibition | NCT00451035 |
| Pioglitazone | PPARγ activation | NCT01751425, NCT02973711 |
| Ruxolitinib | JAK2 inhibition | NCT02889003 |
| Zileuton | ALOX5 inhibition | NCT02047149 |